Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Mandy L. Ford"'
Autor:
Mandy L. Ford, Yini Sun, Jennifer M. Robertson, Aneesh K. Mehta, Marvi Tariq, Scott M. Krummey, Christina R. Hartigan, He Sun, Ching wen Chen
Publikováno v:
Am J Transplant
Belatacept confers increased patient and graft survival in renal transplant recipients relative to calcineurin inhibitors, but is associated with an increased rate of acute rejection. Recent immunophenotypic studies comparing pre-transplant T cell ph
Publikováno v:
Am J Transplant
CTLA-4Ig (belatacept) blocks the CD80/CD86 ligands for both CD28 and CTLA-4; thus, in addition to the intended effect of blocking CD28-mediated costimulation, belatacept also has the unintended effect of blocking CTLA-4-mediated coinhibition. Recentl
Autor:
Danya Liu, Maylene E. Wagener, G. Ding, Idelberto R. Badell, G. M. La Muraglia, Mandy L. Ford
Publikováno v:
American Journal of Transplantation. 18:89-101
Donor-specific antibodies (DSA) are a barrier to improved long-term outcomes following kidney transplantation. Costimulation blockade with CTLA-4-Ig has shown promise as a potential therapeutic strategy to control DSA. T follicular helper (Tfh) cells
Autor:
W. C. Wakwe, Cynthia A. Breeden, Michael C. Lowe, Andrew B. Adams, Alton B. Farris, Mandy L. Ford, Robert M. Townsend, Mustimbo Roberts, David V. Mathews, Joe B. Jenkins, Christian P. Larsen, Steven C. Kim, Elizabeth Strobert
Publikováno v:
American Journal of Transplantation. 17:2285-2299
Recently, newer therapies have been designed to more specifically target rejection in an effort to improve efficacy and limit unwanted toxicity. Belatacept, a CD28-CD80/86 specific reagent, is associated with superior patient survival and graft funct
Publikováno v:
American Journal of Transplantation. 15:2576-2587
Latent viral infections are a major concern among immunosuppressed transplant patients. During clinical trials with belatacept, a CTLA4-Ig fusion protein, patients showed an increased risk of Epstein-Barr virus-associated posttransplant lymphoprolife
Publikováno v:
The FASEB Journal. 34:1-1
Autor:
Christian P. Larsen, Mandy L. Ford, Scott M. Krummey, Aneesh K. Mehta, J. Cheeseman, Peter S. Jang, Jason A. Conger, Allan D. Kirk
Publikováno v:
American Journal of Transplantation. 14:607-614
The CD28/cytotoxic T-lymphocyte antigen 4 (CTLA-4)blocker belatacept selectively inhibits alloreactive T cell responses but is associated with a high incidence of acute rejection following renal transplantation,which led us to investigate the etiolog
Autor:
Christian P. Larsen, Mandy L. Ford, Miriam Cortes-Cerisuelo, Andrew B. Adams, Pamela D. Winterberg, David V. Mathews, Sonia J. Laurie
Publikováno v:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 17(9)
While most human T cells express the CD28 costimulatory molecule constitutively, it is well-known that age, inflammation, and viral infection can drive the generation of CD28null T cells. In vitro studies have demonstrated that CD28null cell effector
Autor:
Aneesh K. Mehta, Christian P. Larsen, Linda Stempora, Allan D. Kirk, Timothy A Weaver, Mandy L. Ford, Denise J. Lo
Publikováno v:
American Journal of Transplantation. 11:22-33
Costimulation blockade (CoB), specifically CD28/B7 inhibition with belatacept, is an emerging clinical replacement for calcineurin inhibitor-based immunosuppression in allotransplantation. However, there is accumulating evidence that belatacept incom
Publikováno v:
Transplant Immunology. 24:94-99
Background Blockade of T cell costimulatory molecules represents a promising new method of attenuating donor-reactive T cell responses to promote graft survival following transplantation. However, recent studies in murine models have shown the presen